Company Active LTD

Company profile

Cambridge Allergy Ltd

Camallergy

Cambridge Allergy Ltd is a UK company with status active founded in 2015 based in South East England.

CRN
09905065
Founded
2015
Age
10

Overview

Legal name
CAMBRIDGE ALLERGY LTD
Region
South East England
Registered address
HOEFORD POINT
BARWELL LANE
GOSPORT
HAMPSHIRE
ENGLAND
PO13 0AU
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Cambridge Allergy Ltd
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

6 events
20 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

04 Jun
2026

Accounts With Accounts Type Total Exemption Full

Accounts PDF pending

AA | Transaction MzUyNDM0MzM0NWFkaXF6a2N4 | Paper/PDF filed

Published 04 Jun 2026 10:28

06 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

07 Dec
2015

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2021
Funded years
2021, 2022
Age at first award
5 years

Projects

2022 Collaborative R&D Lead participant

Clinical trial of CA002 peanut allergy immunotherapy in children

1 Dec 2022 to 30 Nov 2025

Awarded
£1,997,344
Total cost £3,995,487

Peanut allergy is the most common cause of severe reactions and food allergy deaths in children and adults. The continuous need to manage these risks profoundly reduces quality of life of allergy sufferers and their families. Camallergy is pioneering a novel biological oral immunotherapy drug CA002 for the treatment of peanut allergy to protect patients f...

2021 Collaborative R&D Lead participant

CA002 peanut allergy immunotherapy readiness for Phase 3 clinical trials in children

1 Mar 2021 to 31 Aug 2022

Awarded
£1,119,481
Total cost £1,599,258

Peanut allergy is the most common cause of severe reactions and food allergy deaths in children and adults. The continuous need to manage these risks profoundly reduces quality of life of allergy sufferers and their families. Camallergy is pioneering a novel biological oral immunotherapy drug CA002 for the treatment of peanut allergy to protect patients f...

Product types

Collaborative R&D